J B Chemicals & Pharmaceuticals Ltd
J.B. Chemicals and Pharmaceuticals Limited, established in 1976, is one of India's leading pharmaceutical companies. An integrated, publicly-listed organization with a focus on supplying affordable, quality products both in India and internationally, JBCPL is trusted by healthcare professionals globally. [1]
- Market Cap ₹ 26,326 Cr.
- Current Price ₹ 1,687
- High / Low ₹ 2,030 / 1,303
- Stock P/E 40.4
- Book Value ₹ 217
- Dividend Yield 0.71 %
- ROCE 26.7 %
- ROE 20.8 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 20.6% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 35.8%
Cons
- Stock is trading at 7.81 times its book value
- Promoter holding has decreased over last quarter: -5.82%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap Nifty Pharma
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
957 | 1,061 | 1,144 | 1,175 | 1,250 | 1,501 | 1,641 | 1,892 | 2,190 | 2,884 | 3,299 | 3,723 | |
802 | 868 | 917 | 952 | 1,050 | 1,209 | 1,270 | 1,340 | 1,681 | 2,219 | 2,419 | 2,705 | |
Operating Profit | 154 | 193 | 226 | 222 | 199 | 292 | 370 | 552 | 509 | 665 | 880 | 1,018 |
OPM % | 16% | 18% | 20% | 19% | 16% | 19% | 23% | 29% | 23% | 23% | 27% | 27% |
-27 | 10 | 55 | 46 | 39 | 37 | 37 | 116 | 39 | 9 | 34 | 35 | |
Interest | 6 | 7 | 10 | 5 | 3 | 5 | 3 | 7 | 5 | 34 | 41 | 9 |
Depreciation | 27 | 38 | 40 | 46 | 56 | 55 | 65 | 67 | 71 | 112 | 135 | 166 |
Profit before tax | 94 | 159 | 231 | 217 | 179 | 269 | 340 | 594 | 471 | 527 | 738 | 877 |
Tax % | 27% | 29% | 22% | 20% | 29% | 32% | 21% | 25% | 23% | 26% | 26% | 26% |
68 | 114 | 179 | 173 | 128 | 182 | 268 | 447 | 361 | 389 | 543 | 653 | |
EPS in Rs | 4.04 | 6.70 | 10.57 | 10.20 | 7.66 | 11.34 | 17.34 | 28.92 | 23.35 | 25.12 | 35.01 | 41.92 |
Dividend Payout % | 37% | 105% | 24% | 5% | 13% | 22% | 32% | 29% | 35% | 35% | 35% | 37% |
Compounded Sales Growth | |
---|---|
10 Years: | 13% |
5 Years: | 18% |
3 Years: | 19% |
TTM: | 13% |
Compounded Profit Growth | |
---|---|
10 Years: | 20% |
5 Years: | 21% |
3 Years: | 25% |
TTM: | 23% |
Stock Price CAGR | |
---|---|
10 Years: | 31% |
5 Years: | 37% |
3 Years: | 33% |
1 Year: | -5% |
Return on Equity | |
---|---|
10 Years: | 17% |
5 Years: | 20% |
3 Years: | 19% |
Last Year: | 21% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 17 | 17 | 17 | 17 | 17 | 16 | 15 | 15 | 15 | 15 | 16 | 16 |
Reserves | 1,031 | 999 | 1,206 | 1,371 | 1,437 | 1,469 | 1,430 | 1,791 | 2,088 | 2,427 | 2,871 | 3,362 |
93 | 105 | 175 | 49 | 28 | 26 | 29 | 39 | 52 | 547 | 359 | 12 | |
201 | 327 | 244 | 248 | 285 | 283 | 337 | 355 | 382 | 480 | 668 | 788 | |
Total Liabilities | 1,342 | 1,449 | 1,641 | 1,684 | 1,767 | 1,793 | 1,811 | 2,200 | 2,538 | 3,470 | 3,914 | 4,178 |
282 | 301 | 369 | 609 | 570 | 552 | 583 | 565 | 1,204 | 1,822 | 1,925 | 1,899 | |
CWIP | 46 | 55 | 135 | 4 | 17 | 15 | 16 | 26 | 19 | 55 | 76 | 46 |
Investments | 536 | 598 | 612 | 544 | 567 | 589 | 536 | 811 | 146 | 339 | 531 | 488 |
477 | 495 | 525 | 528 | 613 | 636 | 676 | 799 | 1,170 | 1,254 | 1,381 | 1,745 | |
Total Assets | 1,342 | 1,449 | 1,641 | 1,684 | 1,767 | 1,793 | 1,811 | 2,200 | 2,538 | 3,470 | 3,914 | 4,178 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-12 | 143 | 171 | 178 | 116 | 193 | 272 | 335 | 147 | 629 | 789 | 884 | |
-139 | -122 | -52 | -42 | -24 | -28 | 24 | -231 | 4 | -956 | -412 | -290 | |
12 | -23 | -97 | -165 | -59 | -156 | -305 | -87 | -138 | 343 | -374 | -574 | |
Net Cash Flow | -138 | -2 | 22 | -30 | 32 | 9 | -10 | 18 | 13 | 16 | 2 | 20 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 95 | 85 | 85 | 82 | 88 | 73 | 77 | 72 | 86 | 66 | 69 | 75 |
Inventory Days | 108 | 109 | 108 | 131 | 134 | 142 | 149 | 163 | 172 | 136 | 152 | 137 |
Days Payable | 50 | 53 | 56 | 65 | 76 | 76 | 97 | 96 | 96 | 78 | 109 | 112 |
Cash Conversion Cycle | 152 | 141 | 137 | 149 | 145 | 139 | 128 | 139 | 162 | 124 | 112 | 101 |
Working Capital Days | 105 | 60 | 94 | 95 | 107 | 98 | 88 | 95 | 130 | 100 | 88 | 109 |
ROCE % | 13% | 14% | 17% | 12% | 9% | 17% | 22% | 32% | 22% | 22% | 24% | 27% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
22h - Newspaper advertisement - transfer of shares to IEPF
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1d - Prior public notice for equity shareholders of the Company with regard to convening the AGM through Video Conferencing (VC)/Other Audio Visual Means (OAVM)
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
2d - J.B. Chemicals to attend Kotak India Conference, London on June 23-24, 2025; no UPSI to be disclosed.
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
11 Jun - Allotment of Equity Shares on exercise of Stock Options pursuant to Employee Stock Option Scheme
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
5 Jun - Allotment of Equity Shares on exercise of Stock Options pursuant to Employee Stock Option Scheme
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
Concalls
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Dec 2023Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Jan 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Jan 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Aug 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Mar 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Nov 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
-
Sep 2019TranscriptNotesPPT
Revenue Split H1FY24
Domestic Formulations - 55%
Export Formulations - 30%
Contract Manufacturing - 13%
APIs - 2% [1]